NCT07500610 Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.
| NCT ID | NCT07500610 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardiology Research UBC |
| Condition | Peripheral Vascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-09-25 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-09-25 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life. The results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.
Eligibility Criteria
Inclusion Criteria: * Age \>/= 19 years of age * Ability to provide informed consent before any trial-related activities * Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following: 1. Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m/656 feet/2 blocks) for at least 90 days prior to the day of screening based on patient interview. 2. Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or ≥ 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization Exclusion Criteria: * Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening. * Walking ability limited by conditions other than PAD * Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability). * Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening. * Planned arterial revascularisation known on the day of screening. * Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack within 180 days prior to the day of screening. * Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV. * Signs/symptoms of critical limb ischemia (leg gangrene, rest pain, ischemic wounds, etc)
Contact & Investigator
Christopher Fordyce, MD MHS MSc FRCPC
PRINCIPAL INVESTIGATOR
Vancouver General Hospital
Frequently Asked Questions
Who can join the NCT07500610 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Peripheral Vascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500610 currently recruiting?
Yes, NCT07500610 is actively recruiting participants. Contact the research team at jackie.chow@vch.ca for enrollment information.
Where is the NCT07500610 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07500610 clinical trial?
NCT07500610 is sponsored by Cardiology Research UBC. The principal investigator is Christopher Fordyce, MD MHS MSc FRCPC at Vancouver General Hospital. The trial plans to enroll 50 participants.